Literature DB >> 19494434

Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease.

Anis Larbi1, Graham Pawelec, Jacek M Witkowski, Hyman M Schipper, Evelyna Derhovanessian, David Goldeck, Tamas Fulop.   

Abstract

The distribution of peripheral T cell subsets in young and healthy old people is markedly different, characterized by decreased numbers of naïve cells and increased numbers and clonal expansions of memory cells, predominantly in the CD8+ MHC class I-restricted subset. Here, however, we document dramatic alterations in naïve and memory subsets of CD4+ cells in patients with mild Alzheimer's disease (AD), with greatly decreased percentages of naïve cells, elevated memory cells, and increased proportions of CD4+ but not CD8+ cells lacking the important costimulatory receptor CD28. CD4+CD25(high) potentially T regulatory cells with a naïve phenotype are also reduced in AD patients. Together these data provide stronger evidence than hitherto presented for more highly differentiated CD4+ as well as CD8+ T cells in AD patients, consistent with an adaptive immune system undergoing persistent antigenic challenge and possibly manifesting dysregulation as a result.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494434     DOI: 10.3233/JAD-2009-1015

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  74 in total

Review 1.  Human T cell immunosenescence and inflammation in aging.

Authors:  Arsun Bektas; Shepherd H Schurman; Ranjan Sen; Luigi Ferrucci
Journal:  J Leukoc Biol       Date:  2017-07-21       Impact factor: 4.962

2.  Aging affects the proportions of T and B cells in a group of elderly men in a developing country--a pilot study from Pakistan.

Authors:  Iftikhar Alam; David Goldeck; Anis Larbi; Graham Pawelec
Journal:  Age (Dordr)       Date:  2012-07-19

3.  Women's Pregnancy Life History and Alzheimer's Risk: Can Immunoregulation Explain the Link?

Authors:  Molly Fox; Carlo Berzuini; Leslie A Knapp; Laura M Glynn
Journal:  Am J Alzheimers Dis Other Demen       Date:  2018-07-30       Impact factor: 2.035

4.  Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice.

Authors:  Tomomi Kiyota; Jatin Machhi; Yaman Lu; Bhagyalaxmi Dyavarshetty; Maryam Nemati; Izumi Yokoyama; R L Mosley; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2018-03-17       Impact factor: 3.478

5.  miR-155 modulates microglia-mediated immune response by down-regulating SOCS-1 and promoting cytokine and nitric oxide production.

Authors:  Ana L Cardoso; Joana R Guedes; Luís Pereira de Almeida; Maria C Pedroso de Lima
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

Review 6.  Inflammation in neurodegenerative diseases.

Authors:  Sandra Amor; Fabiola Puentes; David Baker; Paul van der Valk
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

7.  Systemic immune system alterations in early stages of Alzheimer's disease.

Authors:  Rongzhen Zhang; Robert G Miller; Catherine Madison; Xia Jin; Ronald Honrada; Will Harris; Jonathan Katz; Dallas A Forshew; Michael S McGrath
Journal:  J Neuroimmunol       Date:  2013-02-04       Impact factor: 3.478

Review 8.  CREB signals as PBMC-based biomarkers of cognitive dysfunction: A novel perspective of the brain-immune axis.

Authors:  Nancy Bartolotti; Orly Lazarov
Journal:  Brain Behav Immun       Date:  2019-01-12       Impact factor: 7.217

Review 9.  Can peripheral leukocytes be used as Alzheimer's disease biomarkers?

Authors:  Kavon Rezai-Zadeh; David Gate; Christine A Szekely; Terrence Town
Journal:  Expert Rev Neurother       Date:  2009-11       Impact factor: 4.618

Review 10.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.